Eli Lilly appoints Ben Basil as President and General Manager of China

Eli Lilly and Company, a world leading pharmaceutical company has appointed a new president for its business in China. According to Eli Lilly’s announcement, Ben Basil, President of North Asia-Pacific and General Manager of Australia and New Zealand will succeed Julio Gay-Ger as the President and General Manager of China. Over the past 3.5 years, Ben has successfully led the NAPAC Hub to double digit annual Sales Revenue growth, while significantly improving productivity. In addition, Ben and his ANZ team have been externally recognized with back-to-back HR Excellence Awards for building a diverse and winning team culture as well as championing Diversity, Equity and Inclusion (DEI).

Over his time with Lilly, Ben has held numerous leadership roles across business units, including the US launch of Verzenio in Breast Cancer and launch readiness of solanezumab in Alzheimer’s Disease as well as the Global Marketing Director, Diabetes Alliance, based in Ingelheim, Germany. Ben holds a Molecular Genetics degree from The Ohio State University and an MBA from the University of North Carolina.